Bacillus anthracis: Causative agent of anthrax;Bacillus anthracis: Agent de la maladie du charbon

Tunisie Medicale

Volumn 79, Issue 12, 2001, Pages 642-646

  Boutiba Ben Boubaker, Ilhem ^a,b   Ben Redjeb, Saïda ^a,b  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b NONE

Author keywords

Anthrax; Bacillus anthracis; Toxines; Zoonose

Indexed keywords

AMOXICILLIN; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PENICILLIN V; STREPTOMYCIN;

ANIMAL DISEASE; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; BLEEDING; DEATH; EDEMA; EPIZOOTIOLOGY; GERMINATION; GRAM POSITIVE BACTERIUM; HUMAN; NECROSIS; NONHUMAN; REVIEW;

ANTHRAX; BACILLUS ANTHRACIS; DISEASE TRANSMISSION; EDEMA; HEMORRHAGE; HUMANS; NECROSIS; PENICILLINS; PROGNOSIS; SOIL MICROBIOLOGY; SPORES; VIRULENCE;

EID: 0035717142     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Chantal J. Actualités de l'anthrax ou fièvre boutonneuse. Méd Trop 1997;57:52S-60S.
2. Vaissaire J. Le charbon bactéridien: accident professionnel d'hier, et toujours présent. Bull. Acad. Vét. De France, 1997;70:93-100.
3. Ramisse F., Hermandez E., Goasdoue JL. Bacillus anthracis et guerre biologique. Bull Soc Fr Microbiol 1998;13:145-151.
4. Kliemann WF and Ruoff KL. Bioterrorism: Implications for the clinical microbiologist. Clin Microbiol Rev 2001;14:364-81.
5. Inglesbi TV, Henderson DA, Bartlett JG et al Anthrax as a biological weapon. JAMA 1999;281:1735-45.
6. Euzéby JP. Systématique, caractères bactériologiques, habitat, pouvoir pathogène, charbon animal et charbon humain, facteurs de pathogénicité, diagnostic, prophylaxie.
7. ème édition, Flammarion Médecine-Science, 1989,879-886.
8. Shafazand S, Doyle R, Ruoss S, Weinacker A and raffin A. Inhalation anthrax, epidemiology, diagnosis, and management. Chest 1999;116:1369-76.
9. Meselson M, Guillemin J, Hugh-Jones M et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-8.
10. CDC Update: CDC summary of confirmed cases of anthrax and background information.
11. World Health Organisation. Guidelines for the surveillance and control of anthrax in human and animals. 3rd edition.
12. ème édition, ESKA 2000; 965-81.
13. Turnbull P, Bowen J, Mann J. Stubborn contamination with anthrax spores. Environmental Health 1996;104:171-3.
14. Turnbull P, Lindeque P, Le Roux J et al. Airborne movement of anthrax spores from carcass sites in the Etosha National Park, Namibia. J Appl Microbiol 1998;84:667-76.
15. Duesbery NS, Webb CP, Leppla SH et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280 734-7.
16. Hammond SE, Hanna PC. Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun 1998;66:2374-8.
17. Sicard JC, Malville M, Fouet A, Mock M. Physiopathologie moléculaire de la maladie du charbon . Rev Méd Vét 1996;147:653-670.
18. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by bacillus anthracis toxin-deficient strains. Infect Immun 1995;63:1369-72.
19. Turnbull P, Leppia SH, Broster MG et al. Antibodies to anthrax toxin in humans and guinea pig and their relevance to protective immunity. Med Microbiol Immnunol 1988;177:293-303.
20. Jackson PJ, Hughes-Jones Me, Adair DM, Green G et al. PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: the present of multiple Bacillus anthracis strains in different victims. Proc Natl Acad Sci USA 1998;95:1224-9.
21. Patra G, Vaissaire J, Weber-Levy m, Le Doujet c, Mock M. Molecular characterization of Bacillus strains involved in outbreak of anthrax in France in 1997. J Clin Microbiol 1998 36:34 12-3-14.
22. Teyssou R, Hance P et Buisson Y. Les infections humaines à Bacillus . Bull Soc Fr Microbiol 1998;13:137-144.
23. Lawrence D, Heitefuss S, Seifert HS. Differentiation of Bacillus anthracis from Bacillus cereus by gas Chromatographic whole -cell fatty acid analysis. J Clin Microbiol 1991;29:1508-12.
24. Ramisse V, Patra G, Garrigue H, Guesdon JL, Mock M. Identification and characterization of Bacillus anthracis by multiplex PCR analysis of sequences on plasmids pXO1 and pXO2 and chromosomal DNA. FEMS Microbiol Lett 1996;145:9-16.
25. Sjosted A, Erikkson U, Ramisse V, Garrigue H. Detection of Bacillus anthracis spores in soil by PCR. FEMS Microbiol Ecol 1997;23:159-68.
26. Keim P. Kalif AS Schupp I et al. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J. Bacteriol 1997;179:818-824.
27. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991;23:333-5.
28. Bradaric N, Punda-Polic V. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 1992; 340-307.
29. Turbull P. Anthrax vaccines: past, present and future. Vaccine 1991;9:533-9.
30. Friedland AM, Welcos SL, Pitt ML et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167;1239-42.
31. Setpanov AV, Marinin LI, Pomerantsev AP, Straritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol 1996;44:155-60.
32. Shlyakhov E, Rubenstein E, Ovikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. Vaccine 1997;15:631-6.